Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
Authors
Keywords
-
Journal
JOURNAL OF HEADACHE AND PAIN
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-06
DOI
10.1186/s10194-020-01138-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
- (2019) Peter J Goadsby et al. BRAIN
- Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
- (2019) John H Krege et al. CEPHALALGIA
- Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
- (2019) Jan Lewis Brandes et al. CEPHALALGIA
- Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
- (2019) Kerry Knievel et al. CEPHALALGIA
- Lasmiditan: First Approval
- (2019) Yvette N. Lamb DRUGS
- Global Neurology: Navigating Career Possibilities
- (2018) Deanna Saylor et al. SEMINARS IN NEUROLOGY
- Lasmiditan is an effective acute treatment for migraine
- (2018) Bernice Kuca et al. NEUROLOGY
- Lasmiditan for the treatment of migraine
- (2017) Matilde Capi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine
- (2017) Bianca Raffaelli et al. EXPERT OPINION ON PHARMACOTHERAPY
- Recent advances in migraine therapy
- (2016) Fabio Antonaci et al. SpringerPlus
- Headache disorders are third cause of disability worldwide
- (2015) Timothy J. Steiner et al. JOURNAL OF HEADACHE AND PAIN
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
- (2012) Peer C. Tfelt-Hansen et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
- (2012) Markus Färkkilä et al. LANCET NEUROLOGY
- Quantifying the return of headache in triptan-treated migraineurs: An observational study
- (2010) Fred Sheftell et al. CEPHALALGIA
- Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan
- (2010) David L Nelson et al. CEPHALALGIA
- Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial
- (2010) Michel D Ferrari et al. CEPHALALGIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started